Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects
Authors:
- 24 September 2010
- journal article
- pharmacogenetics
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 67 (1) , 39-45
Abstract
Ezetimibe is the first lipid-lowering drug that inhibits the intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients. Ezetimibe is readily absorbed, and undergoes rapid and almost complete glucuronidation by UGT, particularly UGT1A1, in enterocytes during its first pass. Genetic polymorphisms of UGT1A1 may decrease ezetimibe glucuronidation. Therefore, we tested the effects of the UGT1A1*6 and *28 alleles on the pharmacokinetics of ezetimibe.Keywords
This publication has 26 references indexed in Scilit:
- Influence of mutations associated with Gilbert and Crigler–Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substratesPharmacogenetics and Genomics, 2007
- Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individualsAnti-Cancer Drugs, 2007
- Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancerOncogene, 2006
- Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndromeHuman Genetics, 2004
- UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer*1Clinical Pharmacology & Therapeutics, 2004
- IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ENZYME(S) RESPONSIBLE FOR THE GLUCURONIDATION OF EZETIMIBE (ZETIA)Drug Metabolism and Disposition, 2004
- Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitorClinical Therapeutics, 2003
- Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male SubjectsDrug Metabolism and Disposition, 2002
- Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663British Journal of Pharmacology, 2000
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000